Copyright
©The Author(s) 2022.
World J Clin Cases. Jan 7, 2022; 10(1): 12-22
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.12
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.12
Medication | Mechanism | Definition of HBV reactivation | Study population | Reactivation rate |
Methotrexate | Suppressive HBV specific cytotoxic T cell response and the production of proinflammatory cytokines | HBV DNA > 103 (copies/mL) | HBsAg-positive | Low risk[29,30] |
HBsAg-negative | Low risk[30] | |||
Leflunomide | Inhibition of the growth of activated lymphocytes by inhibition of dihydro-lactate dehydrogenase | 10-fold rise in HBV-DNA compared to baseline or a switch from undetectable to detectable | HBsAg-positive | High risk, contraindicated[31] |
HBsAg-negative | No data | |||
Corticosteroids | Immunomodulatory and anti-inflammatory | Switch from undetectable HBV DNA to detectable or a 10-fold increase compared with baseline[34] | HBsAg-positive | High risk (> 10 mg, > 4 wk); medium risk (< 10 mg, > 4 wk); low risk (< 10 mg, < 1 wk) |
HBsAg-negative | 1%-1.8%[34,36] | |||
TNF inhibitor | Dampening of the cytokine cascade and suppression of the cytotoxic CD8+ T-cell responses against HBV | An increase of serum HBV DNA levels by greater than 1 logs10 IU/mL or conversion from HBsAg- to HBsAg+ | HBsAg-positive | Medium-high risk (9.1%-75%)[23,38] |
HBsAg-negative | Low risk (0-8.3%)[22,39] | |||
Tocilizumab | Blocks IL-6 signaling by inhibiting its receptor | HBV-DNA level higher than 2.0 log copies/mL | HBsAg-positive | No data |
HBsAg-negative | Low risk (8%)[40] | |||
Tofacitinib | Inhibition of JAK signal pathway | An increase in HBV DNA by greater than 1 to 2 logs10 IU/mL or a reappearance of HBsAg | HBsAg-positive | High risk (100%)[41] |
HBsAg-negative | Low risk (0) | |||
Abatacept | Blocks co-stimulation of T lymphocytes | Conversion from HBsAg- to HBsAg+ | HBsAg-positive | Medium risk[34] |
HBsAg-negative | Low risk[34] |
HBsAg | Anti-HBs | HBeAg | Anti-HBe | Anti-HBc | HBV DNA | ALT | ||||
HBV seronegative | - | +/- | - | - | - | - | Normal | |||
HBV infection | Phase 1 | Chronic HBV infection | + | - | + | - | + | > 20000 IU/mL | Normal | |
Phase 2 | CHB | HBeAg(+) | + | - | + | - | + | > 20000 IU/mL | > 2 ULN | |
Phase 4 | CHB | HBeAg(-) | + | - | - | + | + | > 2000 IU/mL | > 2 ULN | |
Phase 3 | Inactive HBsAg carrier | + | - | - | +/- | + | < 2000 IU/mL | Normal | ||
Phase 5 | Resolved infection | - | +/- | - | + | + | - | Normal |
- Citation: Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases 2022; 10(1): 12-22
- URL: https://www.wjgnet.com/2307-8960/full/v10/i1/12.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i1.12